HeraMed Limited (ASX: HMD), the Australian medical technology company, has formally notified the market of the issue of 15,000,000 unquoted performance rights and 4,000,000 unquoted Options to key management personnel, following Shareholder approval granted at the company's Annual General Meeting on 21 May 2026. The securities were issued on 9 June 2026 and are not intended to be quoted on the ASX, forming part of HeraMed's employee incentive plan. The latest company update brings the total pool of unquoted securities on issue to a sizeable figure across multiple classes, a development investors in the med-tech small-cap space may wish to monitor closely.
Key Points
- Company: HeraMed Limited (ASX: HMD)
- 15,000,000 performance rights (HMDAAH) issued to three directors on 9 June 2026
- 4,000,000 options (HMDAB) issued to one director on 9 June 2026, with various expiry dates and exercise prices
- Both issuances were approved by shareholders at the AGM held on 21 May 2026
- Recipients include Anoushka Gungadin (9,500,000 performance rights), Tim Chapman (3,500,000 performance rights), David Hinton (2,000,000 performance rights), and Sharon Richardson (4,000,000 options)
- HMD ordinary fully paid shares on issue total 1,157,486,602 following this notification
- Investors should watch for any vesting conditions attached to the performance rights and the exercise price terms on the new options
AGM Shareholder Approval Paved the Way for the June 2026 Director Securities Issue
HeraMed's board secured the necessary shareholder mandate for these director incentive securities at the company's Annual General Meeting held on 21 May 2026. Under ASX Listing Rule 7.1, securities issued to directors ordinarily require security holder approval, and the company confirmed that approval was obtained at that meeting. The formal issuance then took place on 9 June 2026, with this latest company update filed on 15 June 2026 to satisfy the notification obligations under ASX Listing Rule requirements and the Appendix 3G reporting framework.
The sequence of events — approval at the AGM followed by issuance within weeks — reflects standard governance practice for listed companies granting Equity-based remuneration to key management personnel. By obtaining approval before issuance, HeraMed ensured the transaction complied with ASX requirements without needing to rely on the issuer's 15% Placement capacity under Listing Rule 7.1. The company noted that the issue did not require a separate exception under Listing Rule 7.2, as shareholder approval was obtained directly under Listing Rule 7.1.
How the 15 Million Performance Rights Are Distributed Across HeraMed's Leadership Team
The 15,000,000 performance rights issued under the HMDAAH security class have been allocated to three named members of HeraMed's key management personnel. Anoushka Gungadin received the largest individual allocation, with 9,500,000 performance rights registered directly in her name. Tim Chapman received 3,500,000 performance rights, held through Inverness Capital Pty Ltd as Trustee for the Match Partners Investment Trust. David Hinton received the remaining 2,000,000 performance rights, registered in his own name.
Performance rights of this type typically vest upon satisfaction of specific conditions — which may include operational milestones, financial targets, or continued service periods — though the specific vesting conditions applicable to these rights are set out in HeraMed's Employee Incentive Plan, a copy of which is available via the company's lodged documentation. The performance rights are classified as unquoted securities and are not intended to be listed for trading on the ASX, meaning their value to recipients is contingent on the satisfaction of those underlying conditions and, ultimately, on HeraMed's share price performance over the relevant period.
Sharon Richardson Receives 4 Million Options Under the HMDAB Class
Alongside the performance rights issuance, HeraMed issued 4,000,000 options to Sharon Richardson, held through Sharon A. Richardson as trustee for the Richardson Living Trust. These options fall under the HMDAB security class, described as options expiring on various dates at various exercise prices. The specific expiry dates and exercise prices applicable to these options were not individually detailed in the notification beyond the class description, and full terms are available through the company's Employee Incentive Plan documentation.
The inclusion of director options with varying expiry dates and exercise prices within a single class (HMDAB) suggests a structured incentive arrangement potentially calibrated to different performance horizons. Sharon Richardson's allocation of 4,000,000 options brings the total HMDAB class on issue to 7,000,000, indicating that prior options under this class were already in existence before this notification. The company confirmed that the options issued to Richardson rank equally in all respects with the existing issued securities in the HMDAB class from their Issue Date.
HeraMed's Full Unquoted Securities Register Now Spans Thirteen Distinct Option and Rights Classes
Following the issuances detailed in this notification, HeraMed's Capital Structure includes a substantial and varied pool of unquoted securities across thirteen distinct classes. The total HMDAAH performance rights on issue now stand at 32,166,140, which includes the 15,000,000 newly issued rights. The HMDAB class — covering options with various expiry dates and exercise prices — now totals 7,000,000 on issue.
Among the broader unquoted options register, notable classes include HMDAAG, representing 70,000,000 options expiring 24 December 2028 at an exercise price of $0.02; HMDAZ, representing 30,428,572 options expiring 20 July 2026 at $0.12; and HMDAAF, representing 33,250,000 options expiring 26 June 2027 at $0.01. The diversity of exercise prices — ranging from $0.01 at the lower end to $0.15 at the higher end — reflects the different market conditions and capital-raising circumstances that applied at the time each class was established. The total unquoted options register, across all classes, represents a meaningful source of potential future share issuance that investors in HMD may Factor into their dilution assessments.
The HMDAZ Options Expiring 20 July 2026 Represent a Near-Term Capital Structure Event
Of particular note in HeraMed's current unquoted securities register is the HMDAZ class, comprising 30,428,572 options with an expiry date of 20 July 2026 and an exercise price of $0.12. With the expiry falling just over one month from the date of this notification, these options represent the most immediate forthcoming capital structure event on HeraMed's options register. Whether holders elect to exercise or allow these options to lapse will depend on the prevailing share price of HMD relative to the $0.12 exercise price at the time.
If exercised in full, the HMDAZ options would bring in gross proceeds calculated at $0.12 per option across 30,428,572 securities — though whether or when any exercise occurs is entirely at the discretion of individual holders and subject to market conditions. The immediate share price impact of the broader notification was not clear from available public information. Investors monitoring HeraMed's capital position may view the July 2026 expiry as a near-term milestone worth tracking.
HeraMed's Ordinary Share Count Sits at Over 1.15 Billion Following the Notification
The company update confirms that HeraMed's total quoted ordinary fully paid shares on issue stand at 1,157,486,602 following the filing of this notification. This figure relates to the quoted HMD ordinary Share Class and does not include the various unquoted options and performance rights detailed throughout the securities register. For a company operating in the medical technology sector at this stage of its development, a share count exceeding one billion is not uncommon, and the figure provides useful context for investors assessing Earnings-per-share metrics or modelling potential dilution from the outstanding options register.
It is worth noting, as the notification itself acknowledges, that the figures in the securities-on-issue table are automatically generated and may not reflect the entity's current Issued Capital if other Appendix 2A, Appendix 3G, or Appendix 3H forms are concurrently being processed by ASX. Investors seeking the most current capital structure information are encouraged to refer to HeraMed's live securities register or the ASX's official announcements platform for any subsequent filings.
HeraMed's Employee Incentive Plan Governs the Terms of All Issued Performance Rights and Options
Both the performance rights and the options issued in this notification are governed by HeraMed's Employee Incentive Plan, a copy of which has been lodged with ASX and is accessible via the company's documentation servers. The plan document sets out the eligibility criteria, vesting conditions, performance hurdles, exercise mechanisms, and treatment of securities upon a change of control or termination of employment — all of which are material to understanding the true economic value and governance implications of the incentive arrangements in place.
Employee and director incentive plans of this kind are a standard feature of ASX-listed companies, particularly in sectors such as medical technology where cash conservation is often a priority and equity-based remuneration is used to align management and director interests with those of long-term shareholders. The key questions for investors examining HeraMed's incentive plan will typically centre on whether the performance conditions are sufficiently stretching to motivate outperformance, and whether the dilutive impact of potential vesting and exercise is proportionate to the value creation expected from management.
What the Director Incentive Structure Signals About HeraMed's Near-Term Retention and Governance Focus
The issuance of performance rights and options to four members of HeraMed's key management personnel — including what appear to be directors based on the AGM approval requirement under Listing Rule 10.14 — signals the board's intention to maintain and incentivise its current leadership team through a combination of time-based and performance-contingent equity. The allocation of the largest individual performance rights Tranche to Anoushka Gungadin, at 9,500,000 rights, suggests she holds a senior role within the organisation, though specific titles were not disclosed in the notification itself.
The structured use of both performance rights and options — two distinct instruments with different risk-reward profiles — indicates a considered approach to remuneration design. Performance rights typically carry no upfront cost to the recipient and deliver value if vesting conditions are met, while options require the holder to pay an exercise price, meaning they only generate a direct economic benefit when the share price exceeds that price. By deploying both instruments across different members of the leadership team, HeraMed's remuneration structure creates layered incentives that may reflect different roles and accountability levels within the company.
Next Milestones for HMD Investors to Monitor Following the Incentive Securities Notification
With the administrative formalities of the director incentive issuance now completed, investors tracking HeraMed may turn their attention to several upcoming events on the company's calendar. The most immediate capital structure milestone is the expiry of the HMDAZ options on 20 July 2026, which will clarify whether approximately 30.4 million options at a $0.12 exercise price are exercised or allowed to lapse. Beyond that, the vesting outcomes of the newly issued performance rights — which are contingent on conditions detailed in the Employee Incentive Plan — will be a longer-term indicator of whether the company's leadership team is meeting the operational and financial targets the board has set.
HeraMed has not, in this company update, provided any operational guidance, Revenue figures, product development updates, or commentary on its commercial progress. The notification is purely administrative in nature, fulfilling the company's continuous disclosure obligations in relation to the issuance of unquoted securities. Investors seeking a fuller picture of HeraMed's Business performance and strategic direction should refer to the company's most recent operational and financial disclosures, including any quarterly activity reports or results announcements filed separately with ASX.





Please wait processing your request...